This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 942431
Submitted by lobbyist on: April 12, 2019 10:28:52 AM
Accepted by Registrar on: April 12, 2019 10:57:13 AM
Designated Filer Information
Van Acker, Anna |
16750 TransCanada Highway | |
Kirkland, QC, H9H 4M7
|
514-428-2638 |
Canada |
Organization Information
MERCK CANADA INC. |
For over a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information about our operations in Canada, visit www.merck.ca and connect with us on YouTube and Twitter @MerckCanada. |
16750 TransCanada Highway | |
Kirkland, QC, H9H 4M7
|
604-643-7996 |
Canada |
Relevant Affiliates
Type:
Business Name | Mailing Address | Contact Information |
---|---|---|
Merck & Co. |
1959 Upper Water Street Suite 900
Halifax, NS B3J 2X2 Canada |
Phone: 604-643-7996 |
Government or Government Agency Funding
Other Controlling or Directing Interests
Active Registration Period
April 12, 2019 | |
October 12, 2019 |
Organization's In-House Lobbyists
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Health | April 12, 2019 | |
Public Agency | Provincial Health Services Authority | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Health | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Provincial Health Services Authority | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Health | September 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Mental Health and Addictions
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Minister | Dix, Adrian | Minister of Health | April 12, 2019 |
Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | April 12, 2019 |
Staff of Minister | Singh, Jasmyn | Minister of Health | April 12, 2019 |
MLA | Barnett, Donna | Cariboo-Chilcotin | April 12, 2019 |
MLA | Brar, Jagrup | Surrey-Fleetwood | April 12, 2019 |
MLA | Cadieux, Stephanie | Surrey South | April 12, 2019 |
MLA | Chen, Katrina | Burnaby-Lougheed | April 12, 2019 |
MLA | Davies, Dan | Peace River North | April 12, 2019 |
MLA | Dean, Mitzi | Esquimalt-Metchosin | April 12, 2019 |
MLA | Furstenau, Sonia | Cowichan Valley | April 12, 2019 |
MLA | Glumac, Rick | Port Moody-Coquitlam | April 12, 2019 |
MLA | Hunt, Marvin | Surrey-Cloverdale | April 12, 2019 |
MLA | Isaacs, Joan | Coquitlam-Burke Mountain | April 12, 2019 |
MLA | Kahlon, Ravi | Delta North | April 12, 2019 |
MLA | Larson, Linda | Boundary-Similkameen | April 12, 2019 |
MLA | Lee, Michael | Vancouver-Langara | April 12, 2019 |
MLA | Letnick, Norm | Kelowna-Lake Country | April 12, 2019 |
MLA | Ma, Bowinn | North Vancouver-Lonsdale | April 12, 2019 |
MLA | Paton, Ian | Delta South | April 12, 2019 |
MLA | Redies, Tracy | Surrey-White Rock | April 12, 2019 |
MLA | Robinson, Selina | Coquitlam-Maillardville | April 12, 2019 |
MLA | Routledge, Janet | Burnaby North | April 12, 2019 |
MLA | Simpson, Shane | Vancouver-Hastings | April 12, 2019 |
MLA | Singh, Rachna | Surrey-Green Timbers | April 12, 2019 |
Public Agency | Provincial Health Services Authority | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Minister | Dix, Adrian | Minister of Health | September 23, 2019 |
Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | September 23, 2019 |
Staff of Minister | Singh, Jasmyn | Minister of Health | September 23, 2019 |
MLA | Barnett, Donna | Cariboo-Chilcotin | September 23, 2019 |
MLA | Brar, Jagrup | Surrey-Fleetwood | September 23, 2019 |
MLA | Cadieux, Stephanie | Surrey South | September 23, 2019 |
MLA | Chen, Katrina | Burnaby-Lougheed | September 23, 2019 |
MLA | Davies, Dan | Peace River North | September 23, 2019 |
MLA | Dean, Mitzi | Esquimalt-Metchosin | September 23, 2019 |
MLA | Furstenau, Sonia | Cowichan Valley | September 23, 2019 |
MLA | Glumac, Rick | Port Moody-Coquitlam | September 23, 2019 |
MLA | Hunt, Marvin | Surrey-Cloverdale | September 23, 2019 |
MLA | Isaacs, Joan | Coquitlam-Burke Mountain | September 23, 2019 |
MLA | Kahlon, Ravi | Delta North | September 23, 2019 |
MLA | Larson, Linda | Boundary-Similkameen | September 23, 2019 |
MLA | Lee, Michael | Vancouver-Langara | September 23, 2019 |
MLA | Letnick, Norm | Kelowna-Lake Country | September 23, 2019 |
MLA | Ma, Bowinn | North Vancouver-Lonsdale | September 23, 2019 |
MLA | Paton, Ian | Delta South | September 23, 2019 |
MLA | Polak, Mary | Langley | September 23, 2019 |
MLA | Redies, Tracy | Surrey-White Rock | September 23, 2019 |
MLA | Robinson, Selina | Coquitlam-Maillardville | September 23, 2019 |
MLA | Routledge, Janet | Burnaby North | September 23, 2019 |
MLA | Simpson, Shane | Vancouver-Hastings | September 23, 2019 |
MLA | Singh, Rachna | Surrey-Green Timbers | September 23, 2019 |
MLA | Yap, John | Richmond-Steveston | September 23, 2019 |
Public Agency | Provincial Health Services Authority | September 23, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Provincial Health Services Authority | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Health | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Health | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Health | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Provincial Health Services Authority | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Provincial Health Services Authority | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Health | April 12, 2019 | |
Public Agency | Provincial Health Services Authority | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Provincial Health Services Authority | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Minister | Dix, Adrian | Minister of Health | April 12, 2019 |
Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | April 12, 2019 |
Staff of Minister | Singh, Jasmyn | Minister of Health | April 12, 2019 |
Public Agency | Health | April 12, 2019 | |
Public Agency | The University of British Columbia | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Mental Health and Addictions
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Minister | Dix, Adrian | Minister of Health | April 12, 2019 |
Staff of Minister | Oreck, Mira | Premier | April 12, 2019 |
Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | April 12, 2019 |
Staff of Minister | Singh, Jasmyn | Minister of Health | April 12, 2019 |
MLA | Brar, Jagrup | Surrey-Fleetwood | April 12, 2019 |
MLA | Chen, Katrina | Burnaby-Lougheed | April 12, 2019 |
MLA | Davies, Dan | Peace River North | April 12, 2019 |
MLA | Furstenau, Sonia | Cowichan Valley | April 12, 2019 |
MLA | Glumac, Rick | Port Moody-Coquitlam | April 12, 2019 |
MLA | Kahlon, Ravi | Delta North | April 12, 2019 |
MLA | Larson, Linda | Boundary-Similkameen | April 12, 2019 |
MLA | Lee, Michael | Vancouver-Langara | April 12, 2019 |
MLA | Letnick, Norm | Kelowna-Lake Country | April 12, 2019 |
MLA | Ma, Bowinn | North Vancouver-Lonsdale | April 12, 2019 |
MLA | Paton, Ian | Delta South | April 12, 2019 |
MLA | Routledge, Janet | Burnaby North | April 12, 2019 |
MLA | Singh, Rachna | Surrey-Green Timbers | April 12, 2019 |
Public Agency | Health | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Minister | Bains, Harry | Minister of Labour | September 23, 2019 |
Minister | Darcy, Judy | Minister of Mental Health and Addictions | September 23, 2019 |
Minister | Dix, Adrian | Minister of Health | September 23, 2019 |
Staff of Minister | Orek, Mira | Premier | September 23, 2019 |
Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | September 23, 2019 |
Staff of Minister | Singh, Jasmyn | Minister of Health | September 23, 2019 |
MLA | Brar, Jagrup | Surrey-Fleetwood | September 23, 2019 |
MLA | Cadieux, Stephanie | Surrey South | September 23, 2019 |
MLA | Chen, Katrina | Burnaby-Lougheed | September 23, 2019 |
MLA | Davies, Dan | Peace River North | September 23, 2019 |
MLA | Furstenau, Sonia | Cowichan Valley | September 23, 2019 |
MLA | Glumac, Rick | Port Moody-Coquitlam | September 23, 2019 |
MLA | Kahlon, Ravi | Delta North | September 23, 2019 |
MLA | Larson, Linda | Boundary-Similkameen | September 23, 2019 |
MLA | Lee, Michael | Vancouver-Langara | September 23, 2019 |
MLA | Letnick, Norm | Kelowna-Lake Country | September 23, 2019 |
MLA | Ma, Bowinn | North Vancouver-Lonsdale | September 23, 2019 |
MLA | Paton, Ian | Delta South | September 23, 2019 |
MLA | Polak, Mary | Langley | September 23, 2019 |
MLA | Routledge, Janet | Burnaby North | September 23, 2019 |
MLA | Singh, Rachna | Surrey-Green Timbers | September 23, 2019 |
MLA | Yap, John | Richmond-Steveston | September 23, 2019 |
Public Agency | Health | September 23, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Health | April 12, 2019 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder for purpose of lobbying
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Engage BC Government on Merck's product pipeline, seek access for Merck's products, provide perspectives on policy changes which may impact access to innovative medicines, explore partnership opportunities and engage in product listing and product agreements with government. Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in British Columbia, including under the British Columbia Drug Plans or under federal legislation. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current immunizations programs, the integration of biosimilar drugs into the British Columbia Drug Plans and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Representations may also concern legislation enacted or proposed in British Columbia to ensure that innovative drugs are excluded from the tendering process covered by such legislation until the expiry of the period covered by their patents. Merck Canada¿s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company¿s main sectors of activities.
Target Contacts
Target Type | Name | Title or Constituency | Date Added |
---|---|---|---|
Public Agency | Health | April 12, 2019 |